<DOC>
	<DOCNO>NCT01288573</DOCNO>
	<brief_summary>This multi-site study plerixafor pediatric cancer patient . The study conduct 2 stage : - Stage 1 dose-escalation study . - Stage 2 open-label , randomize , comparative study use appropriate dose regimen identify Stage 1 dose-escalation study . All participate patient receive standard mobilization regimen per study site practice guideline ( either chemotherapy plus daily granulocyte-colony stimulating factor ( G-CSF ) daily G-CSF alone ) . The change standard mobilization regimen addition plerixafor treatment prior apheresis patient Stage 1 ( dose escalation ) , patient randomize plerixafor plus standard mobilization treatment arm Stage 2 ( randomize , comparative ) . Stage 1 enroll least 27 patient . Stage 2 enroll least 40 patient .</brief_summary>
	<brief_title>A Combined Study Pediatric Cancer Patients Dose Ranging Efficacy/Safety Plerixafor Plus Standard Regimens Mobilization Versus Standard Regimens Alone</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Age 2 &lt; 18 year stage 1 1 &lt; 18 year stage 2 Ewing 's sarcoma , soft tissue sarcoma , lymphoma , neuroblastoma , brain tumor malignancy ( exclude form leukemia ) require treatment high dose chemotherapy autologous transplant rescue therapy Eligible autologous transplantation Recovered acute significant toxic effect prior chemotherapy Adequate performance status ( patient ≥16 year age , define Karnofsky score &gt; 60 patient &lt; 16 year age , define Lansky score &gt; 60 ) Absolute neutrophil count &gt; 0.75 × 10^9/L Platelet count &gt; 50 × 10^9/L Calculated creatinine clearance ( use Schwartz method ) : study Stage 1 , &gt; 80 mL/min/1.73m^2 study Stage 2 , &gt; 60 mL/min/1.73m^2 Aspartate aminotransferase ( AST ) /serum glutamic oxaloacetic transaminase ( SGOT ) , alanine aminotransferase ( ALT ) /serum glutamic pyruvic transaminase ( SGPT ) total bilirubin &lt; 3 × upper limit normal The patient and/or parent/legal guardian willing able provide sign informed consent Patients sexually active must willing abstain sexual intercourse agree use approve form contraception receive plerixafor and/or standard mobilization treatment least 3 month follow plerixafor treatment Any form leukemia A comorbid condition , view Investigator , render patient highrisk treatment complication Previous stem cell transplantation Persistent high percentage marrow involvement prior mobilization prohibit . Ongoing toxicity ( exclude alopecia ) Grade ≥2 result prior chemotherapy Acute infection Fever ( temperature &gt; 38.5°C ) fever 37°C 38.5°C , infection must exclude cause Known HIV seropositivity , AIDS , hepatitis C active hepatitis B infection Positive pregnancy test post pubertal girl History clinically significant cardiac abnormality arrhythmia Use investigational drug approve indication either adult pediatrics within 2 week prior first dose GCSF administer part patient 's plan standard mobilization regimen , and/or study engraftment transplant . If patient investigational drug part anticancer regimen , discuss Sponsor screen . Drugs approve indication use manner consider standard care transplant procedure allow The patient ( and/or parent/legal guardian ) , opinion Investigator , unable adhere requirement study</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>